United States

Eli Lilly and Co (LLY.F)

LLY.F on Frankfurt Stock Exchange

6:27am EDT
Change (% chg)

€-2.96 (-4.12%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for LLY.F


Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)
No analyst recommendations are available for LLY.F.


No Ratios Available.


  LLY.F Industry Sector
P/E (TTM): -- 36.34 36.24
EPS (TTM): -- -- --
ROI: -- 14.45 13.93
ROE: -- 15.22 14.87

BRIEF-Eli Lilly and Co sets quarterly dividend of $0.51/share

* Sets quarterly dividend of $0.51 per share Source text for Eikon: Further company coverage:

Oct 17 2016

Regeneron, Teva take aim at Lilly/Pfizer pain drug

Sept 20 Regeneron Pharmaceuticals Inc and Israeli drugmaker Teva Pharmaceutical Industries on Tuesday said they would co-develop Regeneron's experimental new type of pain drug and together market the medicine if it succeeds in trials and is approved.

Sep 20 2016

BRIEF-EMA recommends approval of three new cancer treatments

* Recommends approval of Eli Lilly and Boehringer Ingelheim's Glyxambi for treatment of type 2 diabetes

Sep 16 2016

BRIEF-Levi Garraway to become senior vice president of global oncology at Lilly

* Levi garraway, m.d., ph.d., to become senior vice president of global oncology at lilly, succeeding richard gaynor, m.d., who is retiring after a distinguished career

Sep 14 2016

BRIEF-Lilly-Health Canada approves new indication for Jardiance tablets

* Health Canada approves new indication for Jardiance (empagliflozin) tablets for adults with type 2 diabetes and established cardiovascular disease Source text for Eikon: Further company coverage:

Aug 11 2016

PRESS DIGEST - Wall Street Journal - Aug 11

Aug 11 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

Aug 11 2016

BRIEF-Eli Lilly names Joshua Smiley senior VP, finance, and treasurer effective Oct 1

* Eli lilly and co says joshua smiley will be appointed to senior vice president, finance, and treasurer effective october 1 Source text for Eikon: Further company coverage:

Aug 10 2016

Lilly breast cancer drug stumbles, but trial continues

U.S. drugmaker Eli Lilly and Co on Wednesday said it would continue a late-stage trial of its experimental breast cancer drug in combination with a widely used treatment even though an independent panel determined the combination therapy failed to meet its interim effectiveness goal.

Aug 10 2016

Panel recommends Lilly continue breast cancer drug study

Aug 10 Eli Lilly and Co said an interim analysis of a late-stage study testing its breast cancer drug abemaciclib by an independent panel showed the treatment did not meet the effectiveness criteria and recommended that the company continue the trial.

Aug 10 2016

BRIEF-Express Scripts adds Lilly's Taltz psoriasis drug to its excluded medicines list

Aug 1 Express Scripts : * says adds Eli Lilly's new Taltz psoriasis drug to its list of excluded medications, making it ineligible for coverage.

Aug 01 2016

Earnings vs. Estimates